US 12,116,620 B2
Compositions and methods for detecting or quantifying parainfluenza virus
Mehrdad Majlessi, Escondido, CA (US); Pamela Douglass, Kansas City, MO (US); and Daniel Kolk, Ramona, CA (US)
Assigned to Gen-Probe Incorporated, San Diego, CA (US)
Filed by Gen-Probe Incorporated, San Diego, CA (US)
Filed on Oct. 16, 2020, as Appl. No. 17/072,890.
Application 17/072,890 is a division of application No. 15/934,273, filed on Mar. 23, 2018, granted, now 10,844,425.
Claims priority of provisional application 62/476,435, filed on Mar. 24, 2017.
Prior Publication US 2021/0040541 A1, Feb. 11, 2021
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6811 (2018.01); C12Q 1/6816 (2018.01); C12Q 1/6851 (2018.01); C12Q 1/6853 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6876 (2018.01); C12Q 1/6888 (2018.01); C12Q 1/70 (2006.01)
CPC C12Q 1/6811 (2013.01) [C12Q 1/6816 (2013.01); C12Q 1/6851 (2013.01); C12Q 1/6853 (2013.01); C12Q 1/686 (2013.01); C12Q 1/6876 (2013.01); C12Q 1/6888 (2013.01); C12Q 1/701 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/166 (2013.01)] 17 Claims
 
1. A composition comprising first, second, third, and fourth amplification oligomers, wherein:
the first amplification oligomer and second amplification oligomer are configured to produce an HPIV-3 amplicon of at least about 50 nucleotides in length comprising at least one Human Parainfluenza Virus 3 (HPIV-3) position located in the range of positions 1350-1360, wherein the first oligomer comprises a target-hybridizing region consisting of the sequence of SEQ ID NO: 25 and the second oligomer comprises a target-hybridizing region consisting of the sequence of SEQ ID NO: 36;
the third amplification oligomer and fourth amplification oligomer are configured to produce an HPIV-4 amplicon, wherein the third oligomer comprises a target-hybridizing region consisting of the sequence of SEQ ID NO: 78 and the fourth oligomer comprises a target-hybridizing region consisting of the sequence of SEQ ID NO: 56;
the composition further comprises a fifth oligomer configured to hybridize to the HPIV-3 amplicon;
the composition further comprises a sixth oligomer configured to hybridize to the HPIV-4 amplicon, wherein the sixth oligomer is a detection probe; and
the sixth oligomer comprises a non-nucleotide detectable label.